Australia and New Zealand consensus statement on the cardiovascular management of patients with chronic lymphocytic leukaemia treated with Bruton's tyrosine kinase inhibitors

Documenti analoghi

• Characteristics of Australian and New Zealand patients with chronic lymphocytic leukaemia: a lymphoma and related diseases registry report
  di: Arina Martynchyk, et al.
  Pubblicazione: (2025)
• Outcomes of allogeneic haemopoietic transplant for chronic lymphocytic leukaemia in the modern era
  di: Luani Barge, et al.
  Pubblicazione: (2025)
• Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era
  di: Diva Baggio, et al.
  Pubblicazione: (2024)
• A single‐institution study of allograft outcomes for chronic lymphocytic leukaemia over 20 years
  di: Rory Bennett, et al.
  Pubblicazione: (2025)
• Outcomes of Bruton tyrosine kinase inhibitors for chronic lymphocytic leukaemia in US veterans with severe renal dysfunction
  di: Chenyu Lin, et al.
  Pubblicazione: (2024)